compound semaglutide medications FDA Warns on Certain Forms of Compounded Compounded' weight-loss drugs are a
Description
As manufacturers direct-to-consumer alternatives have expanded, the cash-pay prices for obesity products have decreased considerably

and 71% in the 40 mg treatment group

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone

Pujadas G, Varin EM, Baggio LL et al (2020) The gut hormone receptor GIPR links energy availability to the control of hematopoiesis

Klausen et al 37 reported adverse effects related to GI symptoms, body weight loss, fatigue, and injection site reactions, and the incidence was higher in the exenatide group compared with the placebo group

DOI: 10.1056/NEJMoa1007137
